Shoji Tetsuaki, Mizugaki Hidenori, Ikezawa Yasuyuki, Furuta Megumi, Takashima Yuta, Kikuchi Hajime, Goudarzi Houman, Asahina Hajime, Kikuchi Junko, Kikuchi Eiki, Sakakibara-Konishi Jun, Shinagawa Naofumi, Tsujino Ichizo, Nishimura Masaharu
First Department of Medicine, Hokkaido University Hospital, Japan.
Intern Med. 2018 Jun 15;57(12):1769-1772. doi: 10.2169/internalmedicine.9741-17. Epub 2018 Feb 9.
This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.
本报告描述了一名66岁患有非小细胞肺癌和静脉血栓栓塞（VTE）的男性病例。在化疗前，最初使用普通肝素（UFH）来控制VTE。然而，将UFH换成华法林或新型口服抗凝剂（NOAC）依度沙班均未成功。随后进行化疗以控制肿瘤，该肿瘤被认为是VTE的主要原因，此前VTE一直通过UFH治疗。化疗使肿瘤缩小后，我们得以成功地将UFH换成依度沙班。控制肿瘤大小和活性使得依度沙班能够作为VTE的维持治疗药物。
